A New Milestone for Inherited Retinal Diseases
According to reports from medcitynews.com, Editas Medicine and Allergan have officially opened patient enrollment for a Phase I/II clinical trial evaluating an experimental in vivo CRISPR/Cas9-based gene therapy. This study represents a significant development for the inherited retinal disease (IRD) community, marking the first time a CRISPR-based medicine is being tested to edit genes directly inside the human body.
Clinical Trial Details for LCA10
The clinical trial, evaluating the treatment known as AGN-151587 (or EDIT-101), focuses on patients with Leber congenital amaurosis 10 (LCA10). LCA10 is a rare inherited form of blindness caused by mutations in the CEP290 gene. According to the source material, the single ascending-dose study is designed to enroll up to 18 patients ranging from 3 to 17 years of age.
Trial locations include four major medical institutions: the Massachusetts Eye and Ear Infirmary in Boston, the Bascom Palmer Eye Institute in Miami, the University of Michigan's W.K. Kellogg Eye Center in Ann Arbor, and Oregon Health and Science University's Casey Eye Institute in Portland. At the time of the announcement, the Boston site was active and open for patient recruitment.
Context and Patient Impact
Unlike previous applications of CRISPR technology that required cells to be extracted, modified outside the body, and re-infused, this in vivo approach delivers the gene-editing treatment directly into the patient. Editas executives noted that the trial brings the medical community one step closer to potential transformative treatments for individuals affected by devastating ocular diseases.
Looking Ahead
As patient recruitment moves forward across the designated clinical sites, researchers and community members await further updates regarding trial progression and the anticipated dosing of the first participants.